Document is current
Any future updates will be listed below
-
Authors
Stüber, Jakob C. https://orcid.org/0000-0002-3406-0664
Richter, Christian P.
Bellón, Junel Sotolongo
Schwill, Martin https://orcid.org/0000-0002-2798-5490
König, Iwo https://orcid.org/0000-0002-1195-5131
Schuler, Benjamin https://orcid.org/0000-0002-5970-4251
Piehler, Jacob https://orcid.org/0000-0002-2143-2270
Plückthun, Andreas https://orcid.org/0000-0003-4191-5306
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 944, Z, Integrated Bioimaging Facility Osnabrück iBiOs, (PI 405/14-1))
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_192689)
- License Information
-
More Information
Article History
Received: 18 November 2020
Accepted: 21 May 2021
First Online: 21 June 2021
Competing interests
: The authors J.C.S., M.S., and A.P. filed the following patents relating to the described bispecific antibodies: Bispecific HER2 Ligands for Cancer Therapy [US20190127481A1; published]; Inventors: Andreas Plückthun, Florian Kast, Martin Schwill, Annemarie Honegger, Rastislav Tamaskovic, Christian Jost; Current Assignee: University of Zurich Her2-binding tetrameric polypeptides [EP3733714; published]; Inventors: Florian Kast, Martin Schwill, Annemarie Honegger, Jakob Stüber, Rastislav Tamaskovic, Andreas Plückthun; Current Assignee: University of Zurich. The University of Zurich has licensed out the invention to Innovent Biologics, Inc. The remaining authors declare no competing interests.
